Hepatic Impairment Study for Lorlatinib in Cancer Patients

Inclusion Criteria: * Histologically or cytologically confirmed solid malignancy or lymphoma that is metastatic or unresectable, and for which standard curative or palliative measures do not exist, or are no longer effective; * Biliary obstruction with a biliary drain or stent; * Neurologically stable gliomas and brain metastases; * ECOG performance status of 0, 1, or 2; * adequate bone marrow function; * adequate pancreatic function; * adequate renal function; * female patients with negative pregnancy test Exclusion Criteria: * untreated esophageal varices; uncontrolled ascites; * episodes of hepatic encephalopathy within the last 4 weeks; * spinal cord compression; major surgery within 4 weeks prior to enrollment; * radiation therapy within 2 weeks prior to enrollment; * last anti-cancer treatment within 2 weeks prior to screening; * previous high-dose chemotherapy requiring stem cell rescue; * prior to irradiation to \>25% of the bone marrow; * gastrointestinal abnormalities; * known prior or suspected hypersensitivity to lorlatinib or lorlatinib tablet; * clinically significant bacterial, fungal or viral infections for non-liver cancer patients; * clinically significant cardiovascular disease; * uncontrolled hypertension; acute pancreatitis with predisposing characteristics; * history of grade 3 or 4 interstitial fibrosis or interstitial lung disease; * active hemoelysis or evidence of biliary sepsis; * prior major gastrointestinal surgery; * concurrent use of known strong CYP3A inhibitors, inducers and P-gp substrates with a narrow therapeutic index; * concurrent use of CYP3A substrates with narrow therapeutic indices; * prior treatment with lorlatinib; active bleeding disorder